API's
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients
Salbutamol Sustained-Release (SR) Pellets are multiparticulate systems designed for controlled oral delivery of Salbutamol Sulphate, a selective β2-adrenergic receptor agonist. Widely used in managing asthma, bronchospasm, and COPD, these pellets provide prolonged bronchodilation, reducing dosing frequency and enhancing patient compliance and therapeutic effectiveness.
| Component | Function |
|---|---|
| Salbutamol Sulphate | Active Pharmaceutical Ingredient (API) |
| Lactose Monohydrate | Filler / Diluent for uniform dispersion |
| Microcrystalline Cellulose (MCC) | Pellet core former / Binder |
| Hydroxypropyl Methylcellulose (HPMC) | Film-former and release modifier |
| Ethyl Cellulose | Sustained-release polymer (coating) |
| Dibutyl Sebacate | Plasticizer for coating flexibility |
| Talc | Anti-adherent in coating |
| Colloidal Silicon Dioxide | Glidant and anti-caking agent |
| Purified Water | Processing solvent (removed during drying) |
Salius Pharma manufactures Salbutamol SR Pellets in USFDA-approved, WHO-GMP, and ISO-certified facilities using advanced pelletization technologies. Our pellets ensure consistent controlled release, excellent flowability, and are fully customizable in strength and particle size to fit varied formulation needs. With comprehensive regulatory support and proven export experience across Africa, LATAM, MENA, and Southeast Asia, Salius Pharma is your trusted partner for premium-quality, sustained-release respiratory APIs.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Salbutamol SR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
Salbutamol SR Pellets provide a sustained-release profile, ensuring gradual and controlled drug delivery over an extended period to maintain consistent bronchodilation and reduce dosing frequency.
We offer Salbutamol SR Pellets at 46% strength by default, with customizable drug load and pellet size to meet specific formulation and therapeutic requirements.
Salius Pharma supplies comprehensive documentation including Certificate of Analysis (CoA), Good Manufacturing Practice (GMP) certificates, Certificate of Pharmaceutical Product (COPP), and Drug Master File (DMF) where applicable, along with regulatory assistance for global markets.
Standard lead time ranges from 2 to 4 weeks post order confirmation. Pellets are packaged in pharma-grade, moisture-resistant containers to ensure stability and quality during transportation and storage.